EyePoint Pharmaceuticals Crecimiento futuro
Future controles de criterios 2/6
Se prevé que los beneficios de EyePoint Pharmaceuticals disminuyan en un 1% al año, mientras que se espera que sus ingresos anuales crezcan en un 44.8% al año. Se prevé que el BPA crezca en un 5% por año. Se espera que la rentabilidad financiera sea de -81.8% en 3 años.
Información clave
-1.0%
Tasa de crecimiento de los beneficios
5.0%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 23.8% |
Tasa de crecimiento de los ingresos | 44.8% |
Rentabilidad financiera futura | -81.8% |
Cobertura de analistas | Good |
Última actualización | 14 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Nov 14Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 8 | -217 | -152 | -190 | 8 |
12/31/2025 | 15 | -178 | -137 | -158 | 11 |
12/31/2024 | 42 | -120 | -130 | -106 | 11 |
9/30/2024 | 46 | -104 | -118 | -113 | N/A |
6/30/2024 | 50 | -87 | -94 | -90 | N/A |
3/31/2024 | 50 | -79 | -17 | -12 | N/A |
12/31/2023 | 46 | -71 | -2 | 2 | N/A |
9/30/2023 | 43 | -100 | 9 | 12 | N/A |
6/30/2023 | 37 | -106 | 12 | 14 | N/A |
3/31/2023 | 40 | -102 | -64 | -62 | N/A |
12/31/2022 | 41 | -102 | -67 | -65 | N/A |
9/30/2022 | 42 | -78 | -71 | -69 | N/A |
6/30/2022 | 41 | -77 | -64 | -64 | N/A |
3/31/2022 | 39 | -67 | -55 | -55 | N/A |
12/31/2021 | 37 | -58 | -50 | -50 | N/A |
9/30/2021 | 33 | -54 | -28 | -28 | N/A |
6/30/2021 | 39 | -42 | -19 | -19 | N/A |
3/31/2021 | 34 | -44 | -14 | -13 | N/A |
12/31/2020 | 34 | -45 | -15 | -14 | N/A |
9/30/2020 | 36 | -40 | -32 | -32 | N/A |
6/30/2020 | 23 | -52 | -48 | -48 | N/A |
3/31/2020 | 26 | -51 | -60 | -60 | N/A |
12/31/2019 | 20 | -57 | -57 | -57 | N/A |
9/30/2019 | 14 | -58 | -56 | -56 | N/A |
6/30/2019 | 12 | -75 | -53 | -53 | N/A |
3/31/2019 | 6 | -98 | -42 | -42 | N/A |
12/31/2018 | 5 | -86 | -34 | -33 | N/A |
9/30/2018 | 3 | -80 | -28 | -28 | N/A |
6/30/2018 | 3 | -53 | N/A | -22 | N/A |
3/31/2018 | 3 | -25 | N/A | -20 | N/A |
12/31/2017 | 3 | -23 | N/A | -20 | N/A |
9/30/2017 | 8 | -17 | N/A | -20 | N/A |
6/30/2017 | 8 | -18 | N/A | -20 | N/A |
3/31/2017 | 7 | -19 | N/A | -20 | N/A |
12/31/2016 | 7 | -19 | N/A | -20 | N/A |
9/30/2016 | 1 | -24 | N/A | -18 | N/A |
6/30/2016 | 2 | -22 | N/A | -16 | N/A |
3/31/2016 | 2 | -20 | N/A | -15 | N/A |
12/31/2015 | 2 | -20 | N/A | -15 | N/A |
9/30/2015 | 2 | -19 | N/A | 10 | N/A |
6/30/2015 | 27 | 6 | N/A | 10 | N/A |
3/31/2015 | 26 | 8 | N/A | 11 | N/A |
12/31/2014 | 28 | 10 | N/A | 13 | N/A |
9/30/2014 | 28 | 11 | N/A | -11 | N/A |
6/30/2014 | 3 | -13 | N/A | -11 | N/A |
3/31/2014 | 4 | -13 | N/A | -11 | N/A |
12/31/2013 | 2 | -14 | N/A | -11 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que EYPT siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que EYPT siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que EYPT siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (44.8% al año) de EYPT crezcan más rápidamente que los del mercado US (9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (44.8% al año) de EYPT crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: EYPT se prevé que no sea rentable en 3 años.